Published by Josh White on 14th May 2026
(Sharecast News) - Theracryf said on Thursday that initial toxicology data from its lead Ox-1 blocker addiction programme showed the drug was well tolerated at very high doses, as clinical trial-enabling work continued ahead of plan.
URL: http://www.digitallook.com/dl/news/story/35934395/...